Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis

Overview

Journal Front Neurol

Specialty Neurology

Date 2019 Oct 15

PMID 31608004

Citations 37

Authors

Sara Gil-Perotin

Jessica Castillo-Villalba

Laura Cubas-Nunez

Raquel Gasque

David Hervas

Josep Gomez-Mateu

Carmen Alcala

Francisco Perez-Miralles

Francisco Gascon

Jose Andres Dominguez

Bonaventura Casanova

Affiliations

Soon will be listed here.

Abstract

Neurofilament light chain protein (NFL) and chitinase3-like1 (CHI3L1) have gained importance recently as prognostic biomarkers in multiple sclerosis (MS). We aimed to investigate NFL and CHI3L1 cerebrospinal fluid (CSF) profiles in multiple sclerosis and the informative and prognostic potential of the individual and combined measures. CSF NFL and CHI3L1 levels were measured in a cross-sectional cohort of 157 MS patients [99 relapsing-remitting (RRMS), 35 secondary progressive (SPMS), and 23 primary progressive (PPMS)]. Clinical relapse and/or gadolinium-enhanced lesions (GEL) in MRI within 90 days from CSF collection by lumbar puncture (LP) were registered and considered as indicators of disease activity. Longitudinal treatment and disability data were evaluated during medical visits with a median follow-up of 50 months. CSF levels of NFL and CHI3L1 were higher in MS patients compared to non-MS controls. In RRMS and SPMS patients, increased NFL levels were associated with clinical relapse, and gadolinium-enhanced lesions in MRI ( < 0.001), while high CHI3L1 levels were characteristic of progressive disease ( = 0.01). In RRMS patients, CSF NFL, and CHI3L1 levels correlated with each other ( = 0.58), and with IgM-oligoclonal bands ( = 0.02 and = 0.004, respectively). In addition, CSF CHI3L1 concentration was a predictor for 1-point EDSS worsening {HR = 2.99 [95% CI (1.27, 7.07)]} and progression during follow-up {HR = 18 [95% CI (2.31, 141.3)]}. The pattern of combined measure of biomarkers was useful to discriminate MS phenotypes and to anticipate clinical progression: RRMS more frequently presented high NFL combined with low CHI3L1 levels, compared to SPMS (HR 0.41 [0.18-0.82]), and PPMS (HR 0.46 [0.19-0.87]), while elevation of both biomarkers preceded diagnosis of clinical progression in RRMS patients (log rank = 0.02). Individual measures of CSF NFL and CHI3L1 are biomarkers of disease activity and progression, respectively. The pattern of combined measure discriminates MS phenotypes. It also predicts the subset of RRMS patients that will progress clinically allowing early intervention.

Citing Articles

No Relation Between Cognitive Impairment, Physical Disability and Serum Biomarkers in a Cohort of Progressive Multiple Sclerosis Patients.

Gajewski B, Karlinska I, Domowicz M, Bednarski I, Swiderek-Matysiak M, Stasiolek M Biomolecules. 2025; 15(1).

PMID: 39858462 PMC: 11763174. DOI: 10.3390/biom15010068.

Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications.

Mwale P, Hsieh C, Yen T, Jan J, Taliyan R, Yang C Mol Neurodegener. 2025; 20(1):7.

PMID: 39827337 PMC: 11742494. DOI: 10.1186/s13024-025-00801-8.

Inflammatory Effects and Regulatory Mechanisms of Chitinase-3-like-1 in Multiple Human Body Systems: A Comprehensive Review.

Liu D, Hu X, Ding X, Li M, Ding L Int J Mol Sci. 2025; 25(24.

PMID: 39769202 PMC: 11678640. DOI: 10.3390/ijms252413437.

CHI3L1 in Multiple Sclerosis-From Bench to Clinic.

Jatczak-Pawlik I, Jurewicz A, Domowicz M, Ewiak-Paszynska A, Stasiolek M Cells. 2025; 13(24.

PMID: 39768177 PMC: 11674340. DOI: 10.3390/cells13242086.

From progression to progress: The future of multiple sclerosis.

Oh J, Giacomini P, Yong V, Costello F, Blanchette F, Freedman M J Cent Nerv Syst Dis. 2024; 16:11795735241249693.

PMID: 38711957 PMC: 11072059. DOI: 10.1177/11795735241249693.

References

Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmestrom C . Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2016; 141(2):296-304. DOI: 10.1111/jnc.13881. View

Rotstein D, Healy B, Malik M, Chitnis T, Weiner H . Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2014; 72(2):152-8. DOI: 10.1001/jamaneurol.2014.3537. View

Sellebjerg F, Royen L, Soelberg Sorensen P, Oturai A, Jensen P . Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Mult Scler. 2018; 25(11):1444-1451. DOI: 10.1177/1352458518794308. View

Mane Martinez M, Olsson B, Bau L, Matas E, Cobo Calvo A, Andreasson U . Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015; 21(5):550-61. PMC: 4390605. DOI: 10.1177/1352458514549397. View

Norden D, Godbout J . Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol. 2012; 39(1):19-34. PMC: 3553257. DOI: 10.1111/j.1365-2990.2012.01306.x. View

Malmestrom C, Axelsson M, Lycke J, Zetterberg H, Blennow K, Olsson B . CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J Neuroimmunol. 2014; 269(1-2):87-9. DOI: 10.1016/j.jneuroim.2014.02.004. View

de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T . Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016; 87(2):141-7. DOI: 10.1212/WNL.0000000000002832. View

Canto E, Reverter F, Morcillo-Suarez C, Matesanz F, Fernandez O, Izquierdo G . Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult Scler. 2011; 18(7):983-90. DOI: 10.1177/1352458511433063. View

Novakova L, Axelsson M, Malmestrom C, Imberg H, Elias O, Zetterberg H . Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. PLoS One. 2018; 13(4):e0194828. PMC: 5882126. DOI: 10.1371/journal.pone.0194828. View

10.

Modvig S, Degn M, Roed H, Sorensen T, Larsson H, Langkilde A . Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. 2015; 21(14):1761-70. DOI: 10.1177/1352458515574148. View

11.

Blennow K, Hampel H, Weiner M, Zetterberg H . Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. DOI: 10.1038/nrneurol.2010.4. View

12.

Teunissen C, Dijkstra C, Polman C . Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2004; 4(1):32-41. DOI: 10.1016/S1474-4422(04)00964-0. View

13.

Sellebjerg F, Bornsen L, Ammitzboll C, Nielsen J, Vinther-Jensen T, Elisabeth Hjermind L . Defining active progressive multiple sclerosis. Mult Scler. 2017; 23(13):1727-1735. DOI: 10.1177/1352458517726592. View

14.

Arrambide G, Espejo C, Eixarch H, Villar L, Alvarez-Cermeno J, Picon C . Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016; 87(11):1076-84. PMC: 5027802. DOI: 10.1212/WNL.0000000000003085. View

15.

Koch M, Kingwell E, Rieckmann P, Tremlett H . The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010; 81(9):1039-43. DOI: 10.1136/jnnp.2010.208173. View

16.

Thompson A, Banwell B, Barkhof F, Carroll W, Coetzee T, Comi G . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017; 17(2):162-173. DOI: 10.1016/S1474-4422(17)30470-2. View

17.

Matute-Blanch C, Rio J, Villar L, Midaglia L, Malhotra S, Alvarez-Cermeno J . Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. J Neuroimmunol. 2017; 303:62-65. DOI: 10.1016/j.jneuroim.2016.12.006. View

18.

Abdo W, van de Warrenburg B, Munneke M, van Geel W, Bloem B, Kremer H . CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology. 2006; 67(3):474-9. DOI: 10.1212/01.wnl.0000227891.25592.8c. View

19.

Mane-Martinez M, Olsson B, Bau L, Matas E, Cobo-Calvo A, Andreasson U . Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. J Neuroimmunol. 2016; 299:112-117. DOI: 10.1016/j.jneuroim.2016.08.004. View

20.

Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y . Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018; 141(8):2382-2391. DOI: 10.1093/brain/awy154. View